drugset / Trial / NCT07631897

Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir Regimens

NCT07631897

Phase 4 Not yet recruiting 60 enrolled Shanghai Public Health Clinical Center
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, multicenter, open-label, parallel-controlled study. The primary objective is to prospectively explore and compare the virological efficacy of Ainuovirine/Lamivudine/Tenofovir and Efavirenz/Lamivudine/Tenofovir regimens combined with rifampicin and isoniazid-based anti-tuberculosis therapy in HIV-infected patients with active tuberculosis. Participants are divided into two groups to compare the virological suppression rate and immunological efficacy between the two antiretroviral regimens. All subjects will receive continuous antiretroviral medication and anti-tuberculosis drugs under medical supervision throughout the study.

Timeline

Start
2026-06
Primary completion
2028-06
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Efavirenz Other / unclassified 400 mg
Subject KM-023 Unknown 150 mg
Background Lamivudine Other / unclassified 300 mg
Background Tenofovir disoproxil fumarate Small molecule 300 mg